| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 31, 2004
From the Mucosal Inflammation Research Group (P.-Y.v.d.W., M.D.H., J.L.W.), University of Calgary, Calgary, Alberta, Canada, and the Department of Gastroenterology and Hepatology (S.F.), University of Perugia, Perugia, Italy. * To whom correspondence should be addressed. E-mail: wallacej{at}ucalgary.ca.
Background--Aspirin-triggered production of 15-(R)-epilipoxin A4 (ATL) has been shown to exert potent antiinflammatory effects and gastric-protective effects, but little is known of its actions on the vasculature. In the present study, we have assessed the contribution of ATL to changes in vascular tone induced by aspirin and have examined the role of nitric oxide (NO) as a mediator of such effects. Methods and Results--Intravenous administration of lipoxin A4 resulted in a short-lived (3 to 4 minutes) reduction in blood pressure (BP; Conclusions--Aspirin-triggered lipoxin synthesis can modulate vascular tone, possibly contributing to changes in regional blood flow during inflammatory reactions, and to the modulation of systemic BP.
Revised on May 17, 2004
Accepted on May 19, 2004
Aspirin-Triggered, Cyclooxygenase-2-Dependent Lipoxin Synthesis Modulates Vascular Tone
Pierre-Yves von der Weid PhD,
13 mm Hg at 2.5 µg/kg). Aspirin administered alone resulted in a significant increase in serum ATL and an increase in BP of
10 mm Hg. When ATL synthesis was inhibited by pretreatment with a selective cyclooxygenase-2 inhibitor (celecoxib) or a 5-lipoxygenase inhibitor (zileuton), the aspirin-induced increase in BP was significantly augmented. These agents alone did not affect BP. A lipoxin receptor antagonist, Boc2, also increased the pressor effects of aspirin. Moreover, immunodepletion of neutrophils, a major source of 5-lipoxygenase, resulted in a significant reduction of ATL formation and augmented aspirins pressor effects. Studies of rat aortic and mesenteric artery ring segments confirmed the vasorelaxant effects of lipoxin A4 and showed them to be endothelium dependent.
This article has been cited by other articles:
![]() |
R. D. Ye, F. Boulay, J. M. Wang, C. Dahlgren, C. Gerard, M. Parmentier, C. N. Serhan, and P. M. Murphy International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family Pharmacol. Rev., June 1, 2009; 61(2): 119 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Levy Myocardial 15-Epi-lipoxin A4 Generation Provides a New Mechanism for the Immunomodulatory Effects of Statins and Thiazolidinediones Circulation, August 29, 2006; 114(9): 873 - 875. [Full Text] [PDF] |
||||
![]() |
Y. Birnbaum, Y. Ye, Y. Lin, S. Y. Freeberg, S. P. Nishi, J. D. Martinez, M.-H. Huang, B. F. Uretsky, and J. R. Perez-Polo Augmentation of Myocardial Production of 15-Epi-Lipoxin-A4 by Pioglitazone and Atorvastatin in the Rat Circulation, August 29, 2006; 114(9): 929 - 935. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Babbin, W. Y. Lee, C. A. Parkos, L. M. Winfree, A. Akyildiz, M. Perretti, and A. Nusrat Annexin I Regulates SKCO-15 Cell Invasion by Signaling through Formyl Peptide Receptors J. Biol. Chem., July 14, 2006; 281(28): 19588 - 19599. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cipollone, M. L. Fazia, A. Iezzi, C. Cuccurullo, D. De Cesare, S. Ucchino, F. Spigonardo, A. Marchetti, F. Buttitta, L. Paloscia, et al. Association Between Prostaglandin E Receptor Subtype EP4 Overexpression and Unstable Phenotype in Atherosclerotic Plaques in Human Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1925 - 1931. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |